Cambridge, UK, 16th March 2023: Mursla is pleased to announce that it will be presenting in-person at the 17th annual BIO-Europe Spring taking place March 20–22, 2023 in Basel, Switzerland.
The event is the largest pharmaceutical and biotech partnering event in Europe this Spring and brings together under one roof the latest innovations which will advance the medicines of tomorrow. It is expected to gather over 2,800 executives from biotech, pharma and finance companies to engage in 15,000+ one-to-one meetings.
The presentation will take place on Tuesday 21st of March 2023 at 13:15 and will be delivered by Pierre Arsène, Founder & CEO. He will discuss the company's innovative liquid biopsy approach and the potential impact of its work on the industry.
Sarah Brereton, Director, Limewash
Tel: 07796 583 223
Notes to Editors
Mursla (Cambridge, UK) is an emergent techbio startup, leveraging extracellular vesicle biology to deliver nextgen multi-omics liquid biopsy tests.
Its first product is a blood test to significantly improve the early detection of liver cancer among high-risk populations so that more patients can benefit from curative treatments (surgery/transplant).
Its test is first-in-class and is differentiated from first generation liquid biopsy blood tests using circulating free DNA since it is tissue-specific, multi-omics and offers real time snapshot of disease biology.
Mursla was selected as UK Life Sciences Innovator 2023 in the Diagnostics and Precision Medicine category.
Discover more: mursla.com